Diagnosis and Treatment Status and Medical Burden of Respiratory Syncytial Virus Infection in Children in China

Condition(s) studied

Investigational drug(s) / intervention(s)

uninvolved: uninvolved

Study summary

To understand the diagnosis and treatment status and medical burden of respiratory syncytial virus (RSV) infection in children in China, and to provide scientific basis for formulating prevention and treatment strategies for children. According to the seven administrative regions of China, namely Northeast, North, Northwest, Southwest, Central, South and East China, 1-3 children's medical institutions were selected from each region, and the cases of bronchiolitis or pneumonia admitted to hospitals and diagnosed as RSV positive by etiology during January 1, 2017 to December 31, 2021 were selected. Demographic data and clinical information were collected, and subgroup analysis was designed to explore the relationship between them and medical expenses and clinical treatment burden.

Eligibility

Primary outcome measure(s)

• hospitalization costs — duration of hospital stay
  hospitalization costs,pharmcost,testcost,testcost

Trial sites (1)

More Beijing Children's Hospital trials in China